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Abstract
Non-alcoholic fatty liver disease is associated with obesity and considered an inflammatory disease. Soluble epoxide
hydrolase (sEH) is a major enzyme hydrolyzing epoxyeicosatrienoic acids and attenuates their cardiovascular protective and
anti-inflammatory effects. We examined whether sEH inhibition can protect against high-fat (HF)-diet–induced fatty liver in
mice and the underlying mechanism. Compared with wild-type littermates, sEH-null mice showed lower diet-induced lipid
accumulation in liver, as seen by Oil-red O staining and triglycerides levels. We studied the effect of sEH inhibition on diet-
induced fatty liver by feeding C57BL/6 mice an HF diet for 8 weeks (short-term) or 16 weeks (long-term) and administering
t-AUCB, a selective sEH inhibitor. sEH inhibition had no effect on the HF-diet–increased body and adipose tissue weight or
impaired glucose tolerance but alleviated the diet-induced hepatic steatosis. Adenovirus-mediated overexpression of sEH in
liver increased the level of triglycerides in liver and the hepatic inflammatory response. Surprisingly, the induced expression
of sEH in liver occurred only with the long-term but not short-term HF diet, which suggests a secondary effect of HF diet on
regulating sEH expression. Furthermore, sEH inhibition attenuated the HF-diet–induced increase in plasma levels of
proinflammatory cytokines and their mRNA upregulation in adipose tissue, which was accompanied by increased
macrophage infiltration. Therefore, sEH inhibition could alleviate HF-diet–induced hepatic steatosis, which might involve its
anti-inflammatory effect in adipose tissue and direct inhibition in liver. sEH may be a therapeutic target for HF-diet–induced
hepatic steatosis in inhibiting systemic inflammation.
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Introduction
Obesity, a chronic inflammatory condition, is becoming a major
health issue worldwide and is closely associated with metabolic
disorders such as diabetes, coronary heart disease and fatty liver
disease [1]. Non-alcoholic fatty liver disease (NAFLD) is one of the
most common forms of chronic liver disease and ranges from pure
fatty liver to the more severe nonalcoholic steatohepatitis and
cirrhosis, with build-up in liver cells of excess neutral lipids, mainly
triglycerides, not due to alcohol consumption. NAFLD is also
considered a risk factor for diabetes and cardiovascular diseases,
independent of other traditional risk factors [2]. With the ‘‘two-
hit’’ hypothesis of the progression of NAFLD, insulin resistance
and the consequent triglycerides accumulation are considered the
first hit and oxidative stress, endoplasmic reticulum stress,
increased proinflammatory cytokines expression and cellular
injury the second hit [3].
Obesity and NAFLD are strongly linked [4]. Increased delivery
of non-esterified fatty acids from adipose tissue in obese individuals
is an important source of excessive lipid deposition in hepatocytes.
Approximately 60% of fat accumulating in the liver is from
adipose tissue [5]. As well, in animal models of high fat (HF)-diet–
induced obesity and metabolic disorder, increased fat in the diet is
another critical source of excess fat in the liver [5]. Moreover,
adipose tissue is considered an endocrine organ that secretes
proinflammatory cytokines such as tumor necrosis factor a (TNF-
a) and interleukin 6 (IL-6), thus contributing to the first and second
hits of NAFLD [6,7,8]. Therefore, treatment strategies specific to
NAFLD include improving insulin sensitivity and inflammatory
status, as well as modifying underlying metabolic risk factors.
Recently, soluble epoxide hydrolase (sEH, EPHX2), function-
ing to enzymatically hydrolyze epoxyeicosatrienoic acids (EETs)
and other fatty acid epoxides, has attracted great interest as a
potential therapeutic target for renal, cardiovascular and
inflammatory diseases [9]. sEH is distributed in various tissues
and highly expressed in liver, kidney and the cardiovascular
system. It is mainly localized in the cytosol of the cell, which
contains the EH catalytic domain in the C-terminal region, and
hydrolyzes EETs and other fatty acid epoxides to their respective
diols [10,11]. EETs have significant protective effects in
regulating vascular, cardiac and renal physiologic functions
[12]. Moreover, EETs are considered anti-inflammatory agents
by their blocking the activation of NF-kB [13]. Inflammation is
believed an initial factor of hepatic lipid accumulation. sEH
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considered a major determinant of EET bioavailability [9,14].
The substrates of sEH include the epoxy products of omega-3
polyunsaturated fatty acids, especially docosahexaenoic acid
(DHA) and eicosapentaenoic acid (EPA) [15], which play a
critical role in relieving hepatic steatosis by regulating nuclear
factors involved in fatty acid de novo synthesis and utilization
[16]. The epoxy metabolites of DHA/EPA have some beneficial
effects, such as anti-inflammatory effects [15,17].
Although sEH inhibition can improve cardiovascular and renal
diseases, the therapeutic potential of sEH inhibition in diet-
induced obesity and lipid metabolism disorder is still largely
unknown [9]. Investigation of genetic polymorphisms in sEH has
suggested its association with plasma triglycerides homeostasis
[18]. sEH expression was found lower in adipose tissue than in
liver and kidney, but total adipose sEH activity was selectively
increased during the development of obesity in mice fed an HF
diet [19]. In a food-induced metabolic-syndrome rat model,
chronic oral treatment with trans-4-[4-(3-adamantan-1-ylureido)-
cyclohexyloxy]-benzoic acid (t-AUCB), a potent sEH inhibitor
[20], alleviated the signs of metabolic syndrome, including lipid
abnormalities and structural and functional changes in the liver
[21].
Considering the relevance of sEH for inflammation, cardiovas-
cular disorders, potential lipid abnormalities, and regulation in
adipose tissue, we investigated the role of sEH in HF-diet–induced
lipid abnormalities and the associated changes in liver by
treatment with sEH inhibition, gene knockout or overexpression
with recombinant human sEH in mice. sEH inhibition could
attenuate HF-diet–induced inflammation in both adipose tissue
and liver, which may be a therapeutic strategy for treating fatty
liver.
Results
sEH Deficiency or Activity Inhibition Reduced HF-diet–
induced Level of Hepatic Triglycerides
EPHX2 gene polymorphism is associated with plasma lipid and
lipoprotein level [18], which suggests that sEH may play a role in
lipid metabolism. We studied the role of sEH in lipid metabolism
and the underlying mechanism in HF-diet–induced lipid metab-
olism disorder in mice with whole-body knockout of Ephx2 (sEH
null) [22] and their wild-type (WT) littermates. HF diet for 8 weeks
increased the body weight and weight of liver and fat tissue in WT
and sEH-null mice (Fig. 1A). Plasma levels of triglycerides and
cholesterol were not affected by an HF diet in sEH-null mice
(Fig. 1B). However, lipid accumulation in liver was lower in sEH-
null than WT mice with an HF diet (Fig. 1C), and triglycerides
content was lower in sEH-null liver (Fig. 1D).
To study whether sEH inhibition can reverse the effect of an
HF diet on fatty liver, we fed mice an HF diet for 8 weeks and
administered a selective sEH inhibitor, t-AUCB, in drinking
water to half of the mice for 4 weeks starting from week 5. t-
AUCB had no effect on HF-diet–increased body weight and fat
tissue weight or plasma level of cholesterol and triglycerides
(Fig. 2A, B) but reduced the HF-diet–induced mild hepatic
steatosis (Fig. 2C, D). Of note, neither sEH deficiency nor
activity inhibition altered the impaired glucose tolerance and
insulin resistance in mice (Fig. S1). To determine whether an HF
diet regulated sEH expression in the liver, which may play a role
in lipid metabolism, we measured the protein expression of sEH
in the liver and found no effect of the diet on sEH expression
and slightly increased sEH activity (Fig. 2E, F). Hydrolase activity
of sEH in liver was largely inhibited by sEH inhibition, but
protein levels of sEH were increased, perhaps through a feedback
mechanism. Thus, sEH expression does not play a major role in
HF-diet–induced hepatic steatosis in these mice.
sEH Inhibition Blocked HF-diet–induced Inflammation
To further investigate the mechanism of sEH inhibition in
regulating hepatic lipid metabolism, we detected the expression of
genes involved in fatty acid synthesis, including liver X receptor
(LXR), carbohydrate response element binding protein
(ChREBP), sterol regulatory element binding protein 1 (SREBP1),
fatty acid synthase (FAS) and acetyl-Coenzyme A carboxylase 1
(ACC1), as well as genes involved in fatty acid b-oxidation,
including peroxisome proliferator-activated receptor a (PPARa),
carnitine palmitoyltransferase 1A (CPT1A), and acyl-CoA oxidase
1 (ACO1). The mRNA levels of these genes were not affected by
sEH inhibition with an HF diet (Fig. S2A, B). Given that chronic
inflammation in diet-induced obesity is associated with lipid
metabolism, we next measured the plasma levels of proinflamma-
tory cytokines, including TNF-a, IL-6, monocyte chemoattractant
protein 1 (MCP-1) and interferon c (IFN-c). The levels of these
cytokines were elevated but not significantly in WT mice fed an
HF diet and were attenuated by sEH inhibition (Fig. 3A); similar
patterns were found in sEH-null mice (Fig. 3B). Levels of TNF-a,
MCP1 and IFN-c were significantly lower in sEH-null than WT
mice fed an HF diet (Fig. 3B).
Because mRNA levels of TNF-a and IL-6 in the liver were not
altered by an HF diet or sEH inhibition (Fig. S2C), liver might be
the targeted organ, instead of the source, of the increased levels of
circulating inflammatory cytokines. Infiltrated inflammatory cells
in adipose tissue and adipocytes were reported to be the major
source of circulating inflammatory cytokines such as IL-6 [23],
which suggests that adipose tissue is an important target for HF-
diet–induced inflammation. Therefore, we detected the mRNA
levels of the macrophage marker F4/80 in epididymal fat tissue of
mice and found increased levels in HF-diet groups and reduced
levels in both sEH-null and sEHI groups (Fig. 3C). Furthermore,
4-week sEH inhibition decreased, although not significantly, the
expression of TNF-a, IL-6, IFN-c and MCP-1 upregulated by the
HF diet in adipose tissue (Fig. 3D). Similar results were observed in
sEH-null mice (Fig. 3E). Therefore, the effect of sEH inhibition or
sEH deficiency on HF-diet–induced lipid accumulation in the liver
might result from anti-inflammatory effects in peripheral tissues,
especially white adipose tissue, which is more sensitive to an HF
diet than liver.
Long-term sEH Inhibition Attenuated HF-induced
Hepatic Steatosis
To explore the long-term protective effect of sEH inhibition on
inflammation and hepatic lipid metabolism, we fed 8-week old
male C57BL/6 mice an HF diet for 16 weeks, and half of the mice
received the sEH inhibitor t-AUCB in drinking water beginning at
3 days before the diet. Long-term HF diet elevated systolic blood
pressure (Fig. 4A), body weight and liver weight (Fig. 4B), plasma
levels of cholesterol (Fig. 4C), and hepatic steatosis (Fig. 4D),
impaired glucose tolerance and induced hyperinsulinemia
(Fig. S3). Although sEH inhibition did not change HF-diet–
increased plasma cholesterol level and insulin resistance, the
elevated blood pressure, hepatic steatosis, and liver content of
triglycerides and cholesterol were significantly attenuated with
sEHI treatment (Fig. 4E). Moreover, the elevated plasma levels of
triglycerides and proinflammatory cytokines such as TNF-a and
IL-6 were attenuated by sEH inhibition (Fig. 4C, F).
sEH Inhibition Attenuates Steatosis in Mice
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Activation of Inflammatory Pathways in Liver
We investigated the role of sEH in the pathogenesis of hepatic
steatosis and found that as compared with an 8-week HF diet, a
16-week HF diet produced 2.6-fold increased sEH protein level in
mouse liver (Fig. 5A) relative to the controls, with reinforced
epoxide hydrolase activity of sEH (Fig. 5B). Furthermore, the long-
term HF-diet activation of inflammatory pathways in the liver,
including increased phosphorylation of JNK and p38 and mRNA
levels of TNF-a and IL-6, was markedly reduced with sEH
inhibition (Fig. 5C and D). To investigate the direct effect of sEH
in the liver of mice, C57BL/6 mice were intravenously injected
with recombinant adenoviruses encoding human sEH (Ad-sEH) or
green fluorescence protein (Ad-GFP). At 7 days post-injection,
sEH mRNA and protein levels and activity were higher in the liver
of mice receiving Ad-sEH than the control Ad-GFP (Fig. 6A–C).
The overexpression of sEH alone was sufficient for elevating the
plasma and liver levels of triglycerides (Fig. 6D–F). Moreover, sEH
overexpression increased the phosphorylation of JNK and p38 and
the mRNA levels of TNF-a and IL-6 in the liver (Fig. 6G and H).
Thus, the secondary upregulation of hepatic sEH with a long-term
HF diet may play an important role in the progression of fatty liver
and hepatic inflammation, from simple hepatic steatosis to
steatohepatitis.
sEHI Attenuated HF-diet–induced Macrophage
Infiltration into Adipose Tissue
Given that sEH inhibition decreased macrophage infiltration
and the expression of pro-inflammatory cytokines in adipose tissue
with a short-term HF diet in mice, we investigated white adipose
tissue of mice fed a 16-week HF diet. The size of adipocytes and
weight of adipose tissue were increased with the diet but were not
affected by sEH inhibition (Fig. 7A). However, sEH inhibition
attenuated HF-diet–induced macrophage infiltration in epididy-
mal fat tissue, as seen by staining for the macrophage markers
CD68 and Mac3 (Fig. 7B), and increased mRNA levels of CD68
Figure 1. sEH deficiency ameliorated high-fat (HF)-diet–induced hepatic steatosis in mice. Wild type (WT) littermates and sEH-null mice
were fed a regular chow or HF diet for 8 weeks. (WT Chow, WT HF: n=6; sEH-null Chow, sEH-null HF: n=8) (A) Body weight, liver weight and
epididymal fat weight. (B) Plasma levels of triglycerides and cholesterol. (C) Oil-red O staining in liver sections. (D) Levels of cholesterol and
triglycerides in liver. Data are mean 6 SEM (* P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0039165.g001
sEH Inhibition Attenuates Steatosis in Mice
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elevated mRNA expression of TNF-a, IL-6, IL-1b and MCP-1
was reduced with sEH inhibition (Fig. 7D), which was closely
linked with their circulating levels.
Discussion
sEH is broadly distributed in mammal tissues, with well-defined
epoxide fatty acids, especially EETs, as excellent substrates. An
Figure 2. 4-week sEH inhibitor administration attenuated 8-week HF-diet–induced triglycerides accumulation in mouse liver. Male
C57BL/6 mice were fed regular chow or a HF diet for 8 weeks with or without sEH inhibitor (sEHI) t-AUCB administration in drinking water from week
5 (n=8 mice/group). (A) Body weight, liver weight and epididymal fat weight. (B) Plasma levels of triglycerides and cholesterol. (C) Oil-red O staining
in liver sections. (D) Levels of triglycerides and cholesterol in liver. (E) Western blot analysis of protein levels of sEH and b-actin as a normalization
control in liver. (F) sEH activity in liver. Data are mean 6 SEM. (* P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0039165.g002
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of mice fed an 8-week chow or HF diet with or without 4-week t-AUCB. (B) Proinflammatory cytokine levels in plasma of WT and sEH-null mice fed an
8-week regular chow or HF diet. (C) mRNA levels of macrophage marker F4/80 in epididymal fat tissue. mRNA levels of tumor necrosis factor a (TNF-a)
and interleukin 6 (IL-6), interferon c (IFN-c), monocyte chemoattractant protein 1 (MCP-1) in epididymal fat tissue of (D) mice fed an 8-week chow or
HF diet with or without 4-week sEH inhibitor and (E) WT or sEH-null mice fed a chow or HF diet. Data are mean 6 SEM. (* P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0039165.g003
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arteries, suppressing adhesion molecule expression [24] and
protecting against insulin resistance [25]. We and others reported
that sEH inhibition relieved angiotensin II (AngII)-induced
hypertension [26] and cardiac hypertrophy [27] and protected
against apoptosis of pancreatic islet cells with streptozotocin-
induced diabetes [28]. sEH inhibition decreased the formation of
aortic atherosclerotic lesions with decreased expression of pro-
inflammatory adhesion molecules in aortas of AngII-infused
apolipoprotein E-null mice fed an atherogenic diet [24]. Given
that the protein level of sEH was increased in aortas of AngII-
infused Wistar-Kyoto rats and EETs had anti-inflammatory effects
in vascular endothelial cells by inhibiting NF-kB and AP-1
expression [13,29], the reduction in lesions was assumed to be
associated with increased levels of EETs and the anti-inflamma-
tory effect of sEH inhibition. Inflammation of local adipose tissue
Figure 4. Full-term sEH inhibitor administration attenuated 16-week HF-diet–induced hepatic steatosis. Male C57BL/6 mice were fed a
regular chow or HF diet for 16 weeks with or without sEHI t-AUCB in drinking water starting from 3 days before diet (Chow 16W: n=10, HF 16W:
n=15, HF 16W+sEHI 16W: n=11). (A) Systolic and diastolic blood pressure. (B) Body weight and ratio of liver weight compared to tibia length. (C)
Plasma levels of triglycerides and cholesterol. (D) Oil-red O staining in liver sections. (E) Levels of triglycerides and cholesterol in liver. (F)
Proinflammatory cytokine levels in plasma. Data are mean 6 SEM. (* P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0039165.g004
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39165Figure 5. sEH inhibition decreased 16-week HF-diet–induced activation of inflammatory pathways in the liver. Male C57BL/6 mice
were fed a regular chow or HF diet for 16 weeks with or without sEHI t-AUCB in drinking water starting 3 days before diet. (A) Western blot analysis of
protein levels of sEH and b-actin as a normalization control in liver. (B) sEH activity in liver. (C) Quantitative RT-PCR analysis of mRNA levels of TNF-a
and IL-6 in liver. (D) Western blot analysis of protein levels of phosphorylated Jun N-terminal kinase (p-JNK), JNK1, p-p38, p38 and b-actin and relative
protein content compared to that of JNK1 or p38. Data are mean 6 SEM. (* P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0039165.g005
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important roles in regulating adipocyte function and lipid
metabolism [30]. sEH expression in adipose tissue did not differ
between HF-diet–induced obese mice and controls, but total
adipose sEH activity was increased, with a large increase in sEH
expression during maturation of adipocytes [19]. A recent study
reported that chronic oral treatment with t-AUCB could attenuate
the signs of metabolic syndrome, including mild steatosis, in a rat
model of metabolic syndrome [21], which supports our findings in
mice with both pharmacological and genetic approaches. As well,
we found that sEH overexpression in liver increased the
inflammatory response, the expression of SREBP1 and its targets
(data not shown), and the level of triglycerides in liver, as well as
plasma level of triglycerides. Thus, in addition to systemic
inflammation, increased sEH expression and activity may
contribute to lipid accumulation in the liver. sEH inhibition may
be important for controlling the pro-inflammatory response and
symptoms of metabolic syndrome, including hepatic steatosis.
The reasons for HF-diet–induced hepatic steatosis are not clear.
Following chronic excessive macronutrient intake, many metabolic
changes, including body weight gain, excess visceral adipose
deposition, insulin intolerance and system inflammation, may
contribute to lipogenesis in liver. TNF-a and lipopolysaccharide
treatment could accelerate hepatic fat accumulation in mice by
upregulating the expression of SREBP1 and FAS [31]. Lee et al.
recently reported that inhibition of inflammation could not
Figure 6. Hepatic sEH overexpression increased hepatic triglycerides accumulation. Male C57BL/6 mice were intravenously infected with
1610
9 PFU adenovirus (Ad)-sEH (n=7) or Ad-GFP (n=6) for 7 days. (A) Western blot analysis of sEH and b-actin in liver. (B) qRT-PCR analysis of mRNA
levels of human sEH and mouse sEH. (C) sEH activity in liver. (D) Plasma levels of cholesterol and triglycerides. (E) Oil-red O staining in liver. (F) Levels
of triglycerides and cholesterol in liver. (G) qRT-PCR analysis of mRNA levels of TNF-a and IL-6 in liver. (H) Western blot analysis of protein levels of p-
JNK, JNK1, p38, p–p38 and b-actin and relative protein content compared to that of JNK1 or p38. Data are mean 6 SEM. (* P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0039165.g006
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in the liver, but blocking macrophage infiltration had positive
effects on protecting against long-term HF-diet–induced damage
[32], which suggests the critical role of inflammation in chronic
fatty liver disease. In our study, hepatic overexpression of sEH
elevated the mRNA levels of TNF-a and IL-6 (Fig. 6G), which
might contribute to the triglycerides accumulation in liver (Fig. 6F).
HF diet for 16 weeks increased the hepatic expression of sEH
protein, but the mechanism is unclear. To determine whether
inflammation is responsible, we treated primary cultured mouse
hepatocytes with the proinflammatory cytokines TNF-a or IL-6
for 24 hr and observed elevated protein level of sEH (data not
shown). Hence, the increased sEH expression might be due to
elevated proinflammatory response to the HF diet. However, with
an HF diet for 8 weeks, the liver expression of sEH and enzymes
involved in fatty acid synthesis were not changed, and the mRNA
level of FAS was lower. The paradoxical lipid-related gene profile
in liver with an HF diet could be due to feedback suppression.
Nevertheless, sEH inhibition did not alter the hepatic lipid-related
gene profile, which suggested an indirect role of sEH inhibition in
regulating hepatic lipid metabolism in obesity, and inhibition of
inflammation in peripheral tissues could not be excluded.
Obesity involves chronic inflammation, with increased macro-
phage infiltration in adipose tissue and secretion of various
cytokines [33,34]. It is associated with many metabolic disorders,
including steatosis and steatohepatitis. Low-grade circulating and
adipose tissue levels of TNF-a and IL-6 were found positively
correlated in obese women, which suggested circulating proin-
flammatory cytokines originating from adipose tissue in obese
individuals [35]. Cytokines could also be secreted by infiltrated
macrophages in adipose tissue as well as adipocytes. We found that
sEH inhibition attenuated HF-diet–induced macrophage infiltra-
tion and elevated mRNA levels of TNF-a, IL-6, IL-1b and MCP1
in adipose tissue (Fig. 7), as well as reduced the circulating levels of
these cytokines. The size of adipocytes and weight of adipose tissue
were not regulated by sEH inhibition, so the decreased proin-
flammatory cytokine secretion might mainly result from reduced
macrophage infiltration in adipose tissue.
Moreover, sEH inhibition or overexpression might result in a
shift of arachidonic acid metabolic pathways: with one pathway
inhibited, other pathways may be activated. Using a metabolomic
approach, we previously demonstrated that chronic administration
of a selective cyclooxygenase 2 inhibitor resulted in .120-fold
increase in blood level of 20-hydroxyeicosatetraenoic acid, a
Figure 7. sEH inhibition attenuated 16-week HF-diet–induced macrophage infiltration in adipose tissue. (A) Ratio of epididymal fat
weight compared to tibia length, and mean size of adiopocytes in epididymal fat of 16-week HF-diet–fed mice with or without full-term sEHI. (B)
Immnohistochemical staining for macrophage markers CD68 and Mac3 in epididymal fat. (C) mRNA levels of CD68 and F4/80 in epididymal adipose
tissue. (D) mRNA levels of TNF-a, IL-6, IL-1b and MCP-1 in epididymal adipose tissue. Data are mean 6 SEM. (* P,0.05, ** P,0.01).
doi:10.1371/journal.pone.0039165.g007
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In addition, omega-3 polyunsaturated fatty acids are substrates of
CYP450 epoxgenases [37], and the epoxy products of DHA and
EPA could be hydrolyzed by sEH. The epoxy metabolite of EPA,
17, 18-epoxyeicosatetraenoic acid, showed anti-inflammatory
effects by decreasing the contractile reactivity and Ca
2+ sensitivity
of TNF-a–pretreated human bronchi [38]. Overexpression of
CYP2J3 increased the generation of EETs and reduced insulin
resistance in both db/db mice and fructose-treated diabetic rats
[39]. Thus, the change in levels of CYP450 metabolites of omega-
3 fatty acids, along with EETs, mediated by hepatic sEH
overexpression might contribute to increased inflammatory
reaction. Metabolite alteration by sEH inhibition mediating the
inflammation and fatty liver should not be excluded.
We propose a model of crosstalk between liver and adipose
tissue for lipid metabolism in the liver regulated by an HF diet and
sEH inhibition (Fig. 8). In the early stage of HF-diet–induced
obesity, inflammation is increased because of inflammatory cell
infiltration, and circulating cytokines such as TNF-a and IL-6 are
elevated; the latter further activates inflammatory signaling in the
liver, which in turn, promotes hepatic lipid accumulation. A long-
term HF diet also upregulates hepatic sEH expression, which may
accelerate HF-diet–induced hepatic damage. sEH inhibition or
sEH knockout improved the inflammatory status in adipose tissue,
thus reduced circulating proinflammatory cytokines in the early
stage of HF diet feeding. Inhibiting the upregulated hepatic
expression of sEH may ameliorate the steatosis induced by a
chronic HF diet treatment. Thus, HF-diet–induced obesity
increased the systemic proinflammatory status, which upregulated
hepatic sEH expression and activated inflammatory signaling in
the liver and in turn, promoted hepatic lipid accumulation. By
attenuating inflammation in both fat tissue and liver, sEH
inhibition may provide a therapeutic strategy in the treatment of
NAFLD.
Materials and Methods
Ethics Statement and Animal Experimental Procedure
The investigation conformed to the Guide for the Care and Use
of Laboratory Animals by the US National Institutes of Health
(NIH Publication No. 85–23, revised 1996). The animal exper-
imental protocol was approved by the Institutional Animal Care
and Use Committee of the Peking University Health Science
Center (LA2011–003). Mice with targeted disruption of Ephx2
gene (sEH null) [22] were back-crossed onto a C57BL/6 genetic
background for more than ten generations as previously described
[40]. Eight-week-old male sEH-null mice and their WT littermates
and C57BL/6 mice were maintained under controlled tempera-
ture and a 12-h light/dark cycle, with free access to water and
standard laboratory chow. Mice were divided into groups for
different diets and treatment as indicated. Each group of sEH-null
and WT mice (n$6 each) or C57BL/6 mice (n$8) were fed a
chow diet (10 kcal% fat, D12450B) or a protein-matched HF diet
(60 kcal% fat, D12492, both Research Diets, New Brunswick, NJ,
USA). For sEH inhibitor (sEHI) treatment, 2 mg t-AUCB
(synthesized in Dr. Bruce D Hammock’s laboratory) was added
to 0.5 ml PEG400 and ultrasonicated until completely dissolved,
and then given to mice (20 mg/L in 100 ml tap drinking water,
starting time as indicated). At the last week of diets, mice were
intraperitoneally injected with glucose (1 g glucose/kg body
weight) or insulin (1 U/kg body weight) after an overnight or a
6-hr fast, and blood glucose was determined by use of a portable
glucometer (ACCU-CHEK II, Roche Diagnostics, Mannheim,
Germany). At the end of treatment, all animals were anesthetized
and killed after a 6-hr fast. Plasma was harvested for measuring
Figure 8. Proposed model for the regulation of hepatic steatosis by sEH in mice. Long-term HF diet increases sEH protein level in the liver
and leads to hepatic lipid accumulation and obesity with increased macrophage infiltration in white adipose tissue. sEH inhibition or deficiency
reduces HF-diet–induced hepatic steatosis by inhibiting systemic inflammation, especially in adipose tissue and liver (long term) as one possible
mechanism. sEH overexpression in the liver with adenovirus injection increased inflammation and hepatic lipid accumulation.
doi:10.1371/journal.pone.0039165.g008
sEH Inhibition Attenuates Steatosis in Mice
PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39165plasma levels of lipids, insulin and cytokines. Plasma insulin was
measured by use of an ELISA kit (Millipore, Billerica, MA, USA)
or an ultrasensitive I
125-linked immunosorbent assay kit (Fu Rui
Inc., Beijing). Tissues were collected and immediately snap-frozen
in liquid nitrogen, and stored at -80
uC.
Adenovirus Purification and Infection In vivo
Recombinant adenoviruses encoding green fluorescence protein
(Ad-GFP) and human sEH (Ad-sEH) were constructed and
amplified as described [27]. Virus particles were purified by
cesium chloride gradient and concentrated by use of Sephadex-G-
25M columns (GE Healthcare, Piscataway, NJ, USA). Titers of
virus (plaque-forming units [PFUs]) were determined in HEK293
cells. For adenoviral infection, 12-week-old C57BL/6 mice were
injected with Ad-GFP or Ad-sEH (n$6) in the tail vein
(1610
9 PFUs diluted in 0.1 ml saline), then fed a regular diet
for the next 7 days before being killed.
Measurement of Lipids in Plasma and Liver
The plasma levels of triglycerides and cholesterol were
measured by use of an automated clinical chemistry analyzer kit
(Biosino Biotech, Beijing). For quantification of hepatic triglycer-
ides and cholesterol levels in liver, tissues were homogenized, and
total lipids were extracted by use of a 2:1 mixture of chloroform:
methanol. Dried lipid residues were dissolved in phosphate
buffered saline containing 5% Triton X2100, and levels of
triglycerides and cholesterol were determined with use of the same
kit used for plasma analysis.
Immunohistochemistry and Oil-red O Staining
Liver and epididymal adipose tissue was fixed, dehydrated, and
embedded, and then blocks underwent sectioning. Frozen liver
sections were stained with Oil-red O. Adipose tissue sections were
incubated with the mouse primary antibody against CD68 (1:200,
Abcam, Cambridge, UK) or rat antibody against Mac3 (1:100;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at
4uC, then anti-mouse or -rat horseradish peroxidase-conjugated
secondary antibody (Zhong-shan Golden Bridge, Beijing) for 1 hr
at 37uC. The nuclei were counterstained with haematoxylin. Slides
were photographed by use of an Eclipse TE2000 inverted
microscope system (Nikon Instruments, Melville, NY, USA) at
6200 magnification.
Western Blot Analysis
Equal amounts of liver protein were separated on 10% SDS-
PAGE and transferred onto PVDF membrane (Millipore), which
was incubated with primary antibodies against sEH (Cayman
Chemical, Ann Arbor, MI, USA), phospho-p38 (Bioworld, Louis
Park, MN, USA), p38, phospho–stress-activated protein kinase
(SAPK)/Jun N-terminal kinase (JNK) (Cell Signaling, Danvers,
MA, USA), total SAPK/JNK1 or b-actin (Santa Cruz Biotech-
nology), then horseradish peroxidase-conjugated anti-rabbit or
anti-mouse IgG antibody (Cell Signaling), and underwent
chemiluminescence detection (Engreen Biosystem, Beijing).
Real-time PCR Analysis
Total RNA in liver and epididymal adipose tissue was isolated
by the Trizol reagent method (Invitrogen, Carlsbad, CA, USA)
and reverse transcribed by use of the First Strand cDNA
Synthesis kit (Thermo Scientific, Rockford, IL, USA). The
amplification reactions were in a volume of 20 ml consisting of
synthesized cDNA, primers and EasyTaq PCR Mix (Transgen
Biotech, Beijing). Eva Green was used to monitor amplification
of DNA by the MX3000P qPCR detection system (Stratagene,
Santa Clara, CA, USA). Fold change in mRNA concentration
was calculated by the comparative CT method. Gene expression
was normalized to b-actin levels. The sequences of primers are in
Table S1.
sEH Activity Assay
Liver tissues were homogenized in deionized water with 1 mM
PMSF, and cytosolic supernatants were obtained by centrifuga-
tion. In total, 100 ml of samples were incubated with or without
20 mM t-AUCB at 30uC for 10 min in 96-well black assay plates,
and 80 mM epoxy fluor 7 in 100 ml reaction buffer (50 mM Tris-
Hcl buffer containing 0.2 mg/ml bovine serum albumin, pH 7.0)
was added to each well. After incubation at 30uC for another
30 min, fluorescence was determined by use of a Spectra Fluor
Plus Xuorescent plate reader (Tecan Systems, San Jose, CA,
USA) with excitation wavelength 330 nm (bandwidth, 20 nm),
emission wavelength 465 nm (bandwidth, 20 nm), and temper-
ature 30uC [41]. sEH activity was the corrected sample
fluorescence intensity calculated by sample fluorescence values
for the sEH inhibitor subtracted from those of the non-sEH
inhibitor.
Cytokine Measurement
The plasma levels of TNF-a, IL-6, MCP-1 and IFN-c were
measured by Cytometric Bead Array with use of a mouse
inflammation kit (BD, San Jose, CA, USA).
Statistical Analyses
The significance of variability was evaluated by unpaired two-
tailed Student’s t test. P,0.05 was considered statistically
significant.
Supporting Information
Figure S1 4-week sEH inhibition or sEH knockout did
not improve HF-diet–induced insulin resistance. C57BL/
6 mice were fed an 8-week regular-chow or HF diet with or
without sEH inhibitor (sEHI) t-AUCB. (A) Intravenous glucose
tolerance test. (B) Plasma level of insulin. (C) Insulin resistance
index (IRI) calculated by plasma insulin level and fasting blood
glucose. sEH wild-type (WT) or sEH-null mice were fed an 8-week
regular-chow or HF diet. (D) Intravenous glucose tolerance test.
(E) Plasma level of insulin. (F) Insulin resistance index (IRI)
calculated by plasma insulin level and fasting blood glucose level.
Data are mean 6 SEM. (* P,0.05).
(TIF)
Figure S2 Expression of genes in the liver of mice.
C57BL/6 mice were fed an 8-week regular-chow or HF diet with
or without sEH inhibitor (sEHI) t-AUCB. qRT-PCR analysis of
mRNA levels in liver of genes involved in (A) fatty acid synthesis,
LXR-a, SREBP1, ChREBP, FAS and ACC; and (B) fatty acid b-
oxidation, PPAR-a, CPT1A and ACO1; and (C) inflammation,
TNF-a and IL-6. Data are mean 6 SEM. (* P,0.05, ** P,0.01).
(TIF)
Figure S3 sEH inhibition did not improve 16-week HF-
diet–induced insulin resistance. Mice fasted for 6 hr from
9:00 am at the end of the week 15, and then were tested for (A)
intravenous glucose tolerance and (B) insulin glucose tolerance. (C)
ELISA of plasma level of insulin. (D) Insulin resistance index (IRI)
was calculated with fasting glucose level and plasma insulin level.
Data are mean 6 SEM. (* P,0.05, ** P,0.01).
(TIF)
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